Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
about
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine.Current challenges in treatment options for visceral leishmaniasis in India: a public health perspectiveMiltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendationsMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisLeishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune responseIn vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasitesShort- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.Treatment of visceral leishmaniasis.Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review.Clinical and experimental advances in treatment of visceral leishmaniasis.Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.Leishmanicidal activity of edelfosine, miltefosine and ilmofosine.Oral miltefosine for the treatment of Indian visceral leishmaniasis.Methods of Control of the Leishmania infantum Dog Reservoir: State of the Art.Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Miltefosine: an oral drug for visceral leishmaniasis.Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice.Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites.Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.Preclinical Studies Evaluating Subacute Toxicity and Therapeutic Efficacy of LQB-118 in Experimental Visceral Leishmaniasis.Leishmaniasis treatment--a challenge that remains: a review.Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.Liposomal resiquimod for the treatment of Leishmania donovani infection.Post-kala-azar dermal leishmaniasis--an overview.Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.Drug target identification in protozoan parasites.Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.Chemotherapy of leishmaniasis: present challenges.Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani.Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes.In vitro prediction of human intestinal absorption and blood-brain barrier partitioning: development of a lipid analog for micellar liquid chromatography.Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions.
P2860
Q24538777-582715C0-9EF4-41FD-9537-2DAD043F9F00Q27930460-238DD074-18D0-4BC6-A737-1145A81972B0Q28073426-ACF37EDF-3931-4A2B-9E4C-F2B36A85FE58Q28088410-55650ED7-40D4-4A52-896E-32FCF3A192D9Q28271849-F82CE6C1-3A28-4720-BC57-89A41755C85EQ28481520-04F4E2D7-8607-48BB-A1C1-663F1435A4C5Q28482212-0F55F0AE-B0B1-4365-98DB-3A1AD627B311Q33691395-7C437F9C-7866-48DB-804C-F777305C4414Q33929849-E3654F43-D848-4B83-A6AB-1812E2BB0903Q33955466-DF973865-7C3F-4F8C-8400-BDB99E51D604Q33982648-9F23FCED-F646-404A-A67C-CDADAEDC3EE2Q34069469-C4540266-4103-468B-A6A4-AEF4E9648AF9Q34289958-276BE228-311B-4AE3-ADEF-53C5EB19728CQ34387541-ED314816-0BDF-46F2-BCD4-76D5204ED35BQ34531203-49EFFD39-418A-49C7-87D1-3211E0E1B94CQ35101238-C64D8F7B-1120-4974-878D-931B818D660BQ35606296-A59846E3-3235-4531-8C4E-AAD78E9DD5D5Q35724996-582F7041-BDF8-47FB-B805-AD6898B3FC6DQ35741989-4223EA5D-670E-4078-AC31-A3DE045DB355Q36237748-79B00554-61CF-4555-8F3A-D135613F33B8Q36564101-77E92470-E7EC-4EC6-8AFD-5A895442E49EQ36576096-29ACD08F-87D5-418B-B256-6E4183B293B1Q36645795-774219F7-54A2-43E0-B933-5D46F83DBCCFQ36933386-66CEE2B4-38E1-4B4C-84EE-B8FDBF3DF8ADQ37128817-F1D7E030-8F6A-4730-9C21-E8BADBB1F704Q37378031-A36C1112-AD02-4C5B-951F-2CAB44593596Q37388288-238B6941-339B-42B4-A1EB-5064A4827756Q37815533-450DE90D-7BD9-453D-9B5C-731E5ED7F540Q38458645-2CAA79DC-A41F-45FA-B114-FF5C7D90A286Q38847814-8BDF2D79-3BC1-40AE-B342-20095A3F6247Q38994980-FCAB7CD2-6249-4C4F-B7D9-BDA979037CE4Q39011875-F74B10B5-7949-409B-A668-0EB1068D01B3Q39262349-3E8094F9-40C8-4740-845F-5C4F1B6C2620Q39444318-D48CA69C-6CFA-405C-9A75-35DD30027146Q39653044-B7041CAA-98C5-4ECF-A747-B7B3F4F7042DQ40460848-1DC209DD-C68A-4016-8259-A3CCE84D262CQ40541880-13E3F2C5-35BC-4C06-A658-DC021051DBC2Q40622211-4B49396F-F2A0-4435-9443-A8C29A51D294Q40639437-7B5EF833-F445-4A0F-8AB5-C48A9B42F6FBQ41893418-92EF938F-0B17-446B-B836-C5C78FED3D13
P2860
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
name
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@ast
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@en
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@nl
type
label
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@ast
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@en
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@nl
prefLabel
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@ast
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@en
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@nl
P2093
P2860
P356
P1476
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice
@en
P2093
P2860
P304
P356
10.1128/AAC.36.8.1630
P407
P577
1992-08-01T00:00:00Z